Breast Cancer Clinical Trials

• Voluntarily sign the informed consent form and comply with protocol requirements;

• Female aged ≥18 and ≤75 years at the time of signing the informed consent form;

• Expected survival time ≥6 months;

• Patients with HER2-positive invasive breast cancer confirmed by histological examination;

• Clinical stage II-III confirmed based on the 8th edition of the American Joint Committee on Cancer (AJCC) staging system before neoadjuvant therapy;

• Treatment-naive trial participants who have not received any anti-tumor therapy for breast cancer;

• Trial participants agree to undergo mastectomy or breast-conserving surgery after completion of neoadjuvant therapy;

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;

• Organ function levels must meet the requirements;

⁃ For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before starting treatment; serum pregnancy must be negative, and the patient must be non-lactating; all enrolled patients should adopt adequate highly effective contraceptive measures throughout the entire treatment cycle and for 7 months after treatment completion.